Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomothearapy by Hsieh, Chen-Hsi et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Radiation Oncology
Open Access Research
Whole pelvic helical tomotherapy for locally advanced cervical 
cancer: technical implementation of IMRT with helical 
tomothearapy
Chen-Hsi Hsieh1,3, Ming-Chow Wei2, Hsing-Yi Lee1, Sheng-Mou Hsiao2, 
Chien-An Chen1, Li-Ying Wang7, Yen-Ping Hsieh8, Tung-Hu Tsai3,9, 
Yu-Jen Chen*3,4,5,6 and Pei-Wei Shueng*1,10,11
Address: 1Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei, Taiwan, 2Departments of Obstetrics and Gynecology, Far 
Eastern Memorial Hospital, Taipei, Taiwan, 3Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, 
4Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan, 5Department of Medical Research, Mackay Memorial Hospital, 
Taipei, Taiwan, 6Graduate Institute of Sport Coaching Science, Chinese Culture University, Taipei, Taiwan, 7School and Graduate Institute of 
Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan, 8Department of Healthcare Administration, Asia University, 
Taichung, Taiwan, 9Department of Education and Research, Taipei City Hospital, Taipei, Taiwan, 10Department of Radiation Oncology, National 
Defense Medical Center, Taipei, Taiwan and 11General Education Center, Oriental Technology Institute, Taipei, Taiwan
Email: Chen-Hsi Hsieh - chenci28@ms49.hinet.net; Ming-Chow Wei - wei@mail.femh.org.tw; Hsing-Yi Lee - nefertari1204@yahoo.com.tw; 
Sheng-Mou Hsiao - smhsiao2@gmail.com; Chien-An Chen - kenk102000@yahoo.com.tw; Li-Ying Wang - liying@ntu.edu.tw; Yen-
Ping Hsieh - fannyhsieh@hotmail.com; Tung-Hu Tsai - thtsai@ym.edu.tw; Yu-Jen Chen* - chenmdphd@yahoo.com; Pei-
Wei Shueng* - shueng@hotmail.com
* Corresponding authors    
Abstract
Background: To review the experience and to evaluate the treatment plan of using helical tomotherapy
(HT) for the treatment of cervical cancer.
Methods: Between November 1st, 2006 and May 31, 2009, 10 cervical cancer patients histologically
confirmed were enrolled. All of the patients received definitive concurrent chemoradiation (CCRT) with
whole pelvic HT (WPHT) followed by brachytherapy. During WPHT, all patients were treated with
cisplatin, 40 mg/m2 intravenously weekly. Toxicity of treatment was scored according to the Common
Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0).
Results: The mean survival was 25 months (range, 3 to 27 months). The actuarial overall survival, disease-
free survival, locoregional control and distant metastasis-free rates at 2 years were 67%, 77%, 90% and
88%, respectively. The average of uniformity index and conformal index was 1.06 and 1.19, respectively.
One grade 3 of acute toxicity for diarrhea, thrombocytopenia and three grade 3 leucopenia were noted
during CCRT. Only one grade 3 of subacute toxicity for thrombocytopenia was noted. There were no
grade 3 or 4 subacute toxicities of anemia, leucopenia, genitourinary or gastrointestinal effects. Compared
with conventional whole pelvic radiation therapy (WPRT), WPHT decreases the mean dose to rectum,
bladder and intestines successfully.
Conclusion: HT provides feasible clinical outcomes in locally advanced cervical cancer patients. Long-
term follow-up and enroll more locally advanced cervical carcinoma patients by limiting bone marrow
radiation dose with WPHT technique is warranted.
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Background
Cervical cancer is the second most frequent cancer among
women worldwide [1]. It has demonstrated the superior-
ity of combined chemotherapy with radiotherapy (RT) in
the treatment of advanced cervix cancer [2,3]. The radia-
tion therapy consists of external beam irradiation to the
primary tumor and corresponding region of lymphatic
drainage, followed by brachytherapy to boost the gross
tumor in the cervix. A significant benefit of chemoradia-
tion on both overall survival and progress-free survival
rate was mentioned [4]. However, grade 3 or 4 haemato-
logical (white cell count, 16% vs. 8%; platelets, 1·5% vs.
0·2%; haematological not otherwise specified, 29% vs.
1%) and gastrointestinal toxicities (9% vs. 4%) signifi-
cantly greater in the concomitant chemoradiation group
than the RT alone group should also be mentioned. Tan et
al. [5] also proposed a late toxicity observation for con-
comitant chemoradiation of locally advanced cervical
cancer. There were 14.5%, 9.4% and 11.4% for grade 3 or
4 urinary, bowel and affecting other organs complica-
tions, respectively.
With the advances in radiotherapy modalities, whole pel-
vic intensity-modulated radiotherapy (WP-IMRT) applied
to gynecologic malignancies with excellent planning tar-
get volume (PTV) coverage and is associated with less
acute gastrointestinal sequelae than conventional whole
pelvic radiotherapy (WPRT) as reported by Mundt et al.
[6]. Under similar target coverage, IMRT is superior to
conventional techniques in normal tissue sparing for the
treatment of cervical cancer and a number of groups have
explored IMRT in the gynecologic setting as a method to
minimize the gastrointestinal, genitourinary, and bone
marrow toxicity that occurs in conventional RT [7-11].
Helical tomotherapy (HT) is a new CT-based rotational
intensity modulated radiotherapy and provides an
impressive ability for highly conformal dose distributions
and simultaneous critical organ sparing ability [12,13].
HT is being tested to apply for gynecologic malignancies
recently and provides encouraging results about excellent
setup accuracy and reducing margins for the external
beam treatment of gynecologic malignancies [14]. How-
ever, this report did not provide the clinical results about
the gynecologic malignancies treated by HT.
In our institute, a Tomotherapy Hi-Art system (Tomother-
apy, Inc., Madison, Wisconsin, USA) was installed and
used for treatment from November 2006. We report here
our initial clinical 2 years experience for patients with
locally advanced cervical cancer with HT, focusing on the
correlation between dosimetry, clinical outcome and early
toxicities.
Methods
Patient's characteristics
Between November 1st, 2006 to May 31, 2009, 10
patients undergoing whole pelvic HT (WPHT) for locally
advanced cervical cancer without pelvic or paraarotic lym-
phadenopathy at Far Eastern Memorial Hospital (FEMH)
were retrospectively enrolled. Staging investigations
included complete history and physical examination,
fiberoptic endoscopic evaluation, complete blood counts,
liver and renal function tests, chest X-ray, magnetic reso-
nance imaging (MRI) scans or computed tomography
(CT) scans of the pelvic region. The disease was staged
according to the International Federation of Gynecology
and Obstetrics (FIGO) criteria [15].
Radiotherapy
Radiotherapy was administered to the whole pelvic region
in 28 fractions totaling 50.4 Gy followed by intracavitary
brachytherapy. The total dose of brachytherapy delivered
was 30 Gy/6 fractions in patients. The total dose delivered
to point A (a reference location 2 cm lateral and 2 cm
superior to the cervical os) was 80.4 Gy in patients; the
total dose delivered to point p (the pelvic wall) was 55.0
Gy in patients. Cisplatin (CDDP) was administered dur-
ing external radiation, beginning on the first day of radia-
tion for 5 weeks concurrent with WPHT. A dose of 40 mg/
m2 CDDP (maximum dose, 70 mg) was used and admin-
istered via a peripheral vein to patients.
Immobilization
A BlueBAG™ immobilization system (Medical Intelli-
gence, Schwabmünchen, Germany) was used for each of
these patients to fix pelvic and extremities. Positioning
was supine with arms up, and feet placed in an ankle
holder. All patients underwent a CT planning scan with
our departmental scanner (Siemens Somatom Plus 4 CT
scanner) from the diaphragm to 5 cm below the ischial
tuberosities. Localization marks were placed on anterior
and lateral sides of the patients at the mid-plane and mid-
line at the level of L4-L5 vertebral body interspace. CT
with 5-mm slice thickness was taken for treatment plan-
ning. Target objects and normal structures were contoured
on a Pinnacle3 treatment planning system (Philips
Healthcare, Madison, Wisconsin, USA). The MRI or CT
images were retrieved on a Pinnacle workstation and
fused with the CT images for contouring of the tumor vol-
ume.
Delineation of target volumes
Delineation and constraints was according to Radiation
Therapy Oncology Group (RTOG) 0418 protocol and the
International Commission on Radiation Units and Meas-
urements reports 50 [16] and 62 [17] recommendations.
The Gross Tumor Volume (GTV) was defined as all knownRadiation Oncology 2009, 4:62 http://www.ro-journal.com/content/4/1/62
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gross disease determined from CT, clinical information,
and MRI. The Clinical Target Volume (CTV) was defined
as areas considered containing potential microscopic dis-
ease. Internal Target Volume (ITV) was defined as the vol-
ume of the vagina and paravaginal soft tissues that is in
both the empty and full bladder CT scans that were done
at the time of simulation and fused together. The Planning
Target Volume (PTV) would provide a 7 mm margin
(anteriorly, posteriorly, laterally, as well as in the superior
and inferior directions) around the nodal CTV and ITV.
The treatment plan would be done on the full bladder
scan. The treatment plan used for each patient would be
based on an analysis of the volumetric dose, including
dose volume histogram (DVH) analyses of the PTV and
critical normal structures. The GTV plus a 7-mm expan-
sion was defined as the primary tumor CTV to account for
microscopic spread, excluding the bowel, bladder, and
rectum if they were not clinically involved); The nodal
CTV should include the internal (hypogastric and obtura-
tor), external, common iliac lymph nodes perinodal tis-
sue, pertinent clips and down to the level of S3.
Identification of the CTV usually began with the identifi-
cation of the iliac vessels. The average margin would be 7
mm. Bone and intraperitoneal small bowel should be
excluded from the CTV; also, iliopsoas muscle that lies
adjacent to clinically negative lymph nodes should also be
excluded from the CTV. Approximately 1.5 cm of tissue
anterior to the S1, S2 and S3 sacral segments was usually
added to the CTV in order to include the presacral lymph
nodes and uterosacral ligaments. The most antero-lateral
external iliac lymph nodes that lied just proximal to the
inguinal canal should be excluded from the CTV. The CTV
of the nodes should end 7 mm from L4/L5 interspace to
account for the PTV. The PTV for nodes stopped at L4/L5
interspace. The vaginal and parametrial CTV should actu-
ally be an ITV, which will account for internal organ
motion. The inferior limit was usually around the level of
the upper third of the symphysis pubis but could be indi-
vidualized based on inferior spread of the patient's tumor.
The lateral margin of the vaginal PTV should be to the
obturator muscle. However, at least 3 cm of the vagina
needed to be treated or at least 1 cm below the obturator
foramen. The 90% isodose surface covered between 95%
and 98% of the PTV 50.4, or volumes of overdose exceed
115% < 5% of the PTV 50.4 volume could be considered
acceptable. The field width, pitch, and modulation factor
(MF) usually used for the WPHT treatment planning opti-
mization were 2.5 cm, 0.32 and 3.0, respectively. All
patients received daily megavoltage computed tomogra-
phy (MVCT) acquisitions for setup verification [18].
Normal structures will be contoured using the full-blad-
der CT scan. The OARs (i.e., bladder, rectum, sigmoid,
small bowel, and femoral heads) were contoured as solid
organs. Dose-volume constraints for normal tissues were
as follows: small bowel (2 cm above the most superior
vessel contour) < 30% to receive ≥ 40 Gy, minor deviation
30% to 40 Gy; Rectum < 60% to receive ≥ 30 Gy, minor
deviation 35% to 50 Gy; Bladder < 35% to receive ≥ 45
Gy, minor deviation 35% to 50 Gy; Femoral head ≤ 15%
to receive ≥ 30 Gy, minor deviation 20% to 30 Gy.
Intracavitary brachytherapy
An iridium-192 (high-dose-rate) source was used with
standard Fletcher-Suit-Delclos intracavitary applicators.
Patients were treated twice a week after WPHT completed
for 3 weeks, with a prescribed dose of 500 cGy per fraction
to Point A. The high-dose rate (HDR) source dwell times
were manually calculated based on our institutional sys-
tem of empiric intracavitary irradiation rules. Postimplan-
tation dosimetry was performed with the GENIE
treatment planning system v1.0.4 (Nucletron, Nether-
land), and included calculation of dose to the "classical"
Point A bilaterally (a reference location 2 cm lateral and 2
cm superior to the cervical os), pelvic sidewall bilaterally
(Point P, defined as the point 2 cm above the top of the
colpostat and 6 cm lateral to midline), and the rectal
point and bladder point as defined by the International
Commission on Radiation Units and Measurements [19].
For each implant, point doses to Points A and P, the blad-
der point, and the rectal point were recorded; after com-
pletion of therapy, the doses for the six implants were
summed. There is no standard or universally accepted
fraction size for HDR brachytherapy. At our institution we
have chosen to use the fraction size of 500 cGy.
Conventional treatment planning for comparison
Conventional whole pelvic radiation therapy (WPRT)
plans were generated using Pinnacle3 treatment planning
system (Philips Healthcare, Madison, Wisconsin, USA).
The isocenter was placed at the geometric center of the
PTV. A 4-field "box" plan was designed using 6-MV pho-
tons with apertures shaped to the PTV in each beam's eye-
view. The pelvic field extended from the upper margin of
L5 to the midportion of the obturator foramen or the low-
est level of disease, with a 2-cm margin, and laterally 1.5
cm beyond the lateral margins of the bony pelvic wall (at
least 7 cm from the midline). For the lateral fields, the
anterior border was the pubic symphysis and the posterior
border was the space between S2 and S3. The fields could
be modified to include areas of known tumor and wedges
were used as needed. All plans were normalized to cover
98% of the PTV with 50.4 Gy. The 2% underdose repre-
sents those voxels at the periphery. This normalization
provided conformal coverage while minimizing dose
nonuniformity within the target.
Dose-volume analysis of treatment plans
Dose-volume histograms (DVHs) of the PTVs and the crit-
ical normal structures were analyzed accordingly. ForRadiation Oncology 2009, 4:62 http://www.ro-journal.com/content/4/1/62
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PTVs, we evaluated the volume, the volume covered by
95% of the prescription dose (V95), and the minimum
doses delivered to 5% (D5) and 95% (D95) of the PTV. The
critical organs with functional subunits organized in a
series were examined. The conformal index (CI) and the
uniformity index (UI) had been used to evaluate the con-
formity and uniformity of the plan. The volume received
the mean dose for PTV generated from the DVH. The con-
formal index (CI) for PTV was calculated using the for-
mula CIICRU = VTV/VPTV, where VTV was the ratio of the
treated volume enclosed by the prescription isodose sur-
face and VPTV was the planning target volume [17]. The
uniformity index (UI) was defined as UI = D5/D95, where
D5 and D95 were the minimum doses delivered to 5% and
95% of the PTV reported previously [20].
Toxicity
Interruptions in radiotherapy might be necessitated by
uncontrolled diarrhea, or other acute complications. If
radiation therapy was held, then chemotherapy would
also be held. Chemotherapy stopped at the completion of
RT. If chemotherapy was held, radiation therapy would
continue. Radiation was only stopped in cases of grade 4
hematologic or non-hematologic toxicity until toxicity
resolved to at least grade 3. CDDP was withheld in any
case involving grade 3 toxicity until the toxicity regressed
to any grade of <3; in patients with grade 3 toxicity that
persisted >2 weeks, chemotherapy was no longer admin-
istered.
Follow-up
Upon treatment completion, patients were evaluated
every 3 months for the first year, every 4 months during
the second year, every 6 months during the third year, and
annually thereafter. At each visit, a physical and pelvic
examination, blood counts, clinical chemistry, and chest
x-rays were performed. Computed tomography (CT) scan,
ultrasound (US), and other imaging studies were con-
ducted when appropriate. Suspected cases of persistent or
recurrent disease were confirmed by biopsy whenever pos-
sible. Acute and late toxicities (occurring >90 days after
beginning RT) were defined and graded according to the
Common Terminology Criteria for Adverse Events v3.0
(CTCAE v3.0).
Statistical methods
Descriptive statistics (mean, median, proportions) were
calculated to characterize the patient, disease, and treat-
ment features as well as toxicities after treatment. The
overall survival (OS), progression-free survival (PFS),
locoregional progression-free (LRPF), and distant metas-
tases-free (DMF) rates were estimated using the Kaplan-
Meier product-limit method. Progression was defined as a
50 percent increase in the product of the two largest diam-
eters of the primary tumor or metastasis. Progression-free
survival was calculated from the date of pathologic proof
to the date of the first physical or radiographic evidence of
disease progression, death, or the last follow-up visit. Sur-
vival was calculated from the date of pathologic proof to
the date of death or the last follow-up visit. All analyses
were performed using the Statistical Package for the Social
Sciences, version 12.0 (SPSS, Chicago, IL, USA).
Results
Patient characteristics
Ten women were included. They had a median age of 58
years (range, 33-72 years). All belong to FIGO Stage IIB
and IIIB. The medium tumor volume was 45.9 cm3. The
medium weekly cycles of chemotherapy were 5 weeks.
Seventy percent of patients could complete 4 weekly
cycles of chemotherapy. All of the patients were treated
with definitively concurrent chemotherapy with WPHT
followed by brachytherapy. (Table 1)
Treatment outcome
The mean survival was 25 months (range, 3 to 27
months). The actuarial 2-year overall survival, progress-
free survival, locoregional control and distant metastasis-
free rates were 67%, 77%, 90% and 88%, respectively. The
2-year survival, progression-free, locoregional-progres-
sion-free and distant metastasis-free patient number over
all patients are 9/10, 8/10, 9/10 and 9/10, respectively.
Ninety percent of patients were surviving at the time of
this report.
Dose-volume analysis and comparison for WPHT and 
WPRT
The WPHT for UI and CI was 1.07 ± 0.05 and 1.01 ± 0.05,
respectively. The UI and CI for individual patient are plot-
ted in Figures 1A and 1B, respectively. Dose-volume histo-
grams statistics for the organs at risk are described in table
2. WPHT provided better critical organs sparing than
WPRT in the mean dose and the other parameters for rec-
tum, bladder and intestine with a statistically significant
level (p  value < 0.01), respectively. WPHT provided
impressive ability of high dose declining for OARs than
WPRT. However, WPHT had poorer results for right and
left side pelvic bone sparing than WPRT due to lacking of
V10 and V20 constraint for planning initially.
Acute and subacute toxicity
Acute toxicity of radiation therapy within chemotherapy
and late toxicity is detailed in Additional file 1. One grade
3 of acute toxicity for diarrhea, thrombocytopenia and
three grade 3 of leucopenia were noted during CCRT.
Only one grade 3 of subacute toxicity for thrombocytope-
nia was noted. There was no grade 3 or 4 subacute toxici-
ties for anemia, leucopenia, genitourinary or
gastrointestinal.Radiation Oncology 2009, 4:62 http://www.ro-journal.com/content/4/1/62
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Discussion
In our preliminary results of locally advanced cervical can-
cer receiving WPHT concurrent with chemotherapy fol-
lowed by brachytherapy, HT provides feasible outcomes
and acceptable toxicity during and after CCRT.
The 2-year estimate of OS, PFS, locoregional failure only
and distant metastasis only rate in the RT plus weekly
CDDP reported by randomized trials was 67 - 71%, 64 -
84%, 10 - 25% and 6 - 11%, respectively [2,3,21]. The
overall survival, disease-free survival, locoregional failure
and distant metastasis rate at 2 years in our institute are
67%, 77%, 10% and 12%, respectively. The clinical results
of WPHT concurrent with weekly CDDP following by
HDR brachytherapy at our institute suggest WPHT is fea-
sible for locally advanced cervical carcinoma patients.
Adding more beams would lead to improved conformal-
ity without affecting the value of the objective function
[20]. The CI is usually larger than 1, indicating that a por-
tion of the prescription dose was delivered outside the
PTV. The greater the CI, the less is the dose conformity to
the PTV [20]. The greater UI indicates higher heterogene-
ity in the PTV [22]. In the current study, the UI and CI for
WPHT was 1.07 ± 0.05 and 1.01 ± 0.05, respectively.
WPHT provides the impressed conformality and uniform-
ity for locally advanced cervical carcinoma patients. The
UI and CI for individual patient are described in Fig. 1A
and 1B, respectively.
Despite the clear efficacy of a combined modality
approach in locally advanced cervical cancers [2,3,21],
toxicity can be considerable. For locally advanced cervical
cancer treated with CCRT, the rates of grade 3 acute toxic-
ities for GI effects were 7 - 9% [2,3,23]. For moderate acute
hematologic effects, the happening rate during CCRT was
reported from 23% to 37% [2,3,23]. In the current study,
the moderate acute toxicities during CCRT are listed as fol-
low: one (1/10) for diarrhea, three (3/10) for leukopenia
and one (1/10) for thrombocytopenia. (Additional file 1)
Table 1: Patient characteristics
Variable No. of patient (%)
Age (years)
Median (range) 58 (33-72)
Gender
Female 10
(100%)
Karnofsky performance status
< 70 0
≥ 70 10
(100%)
Pathology
Squamous cell carcinoma 7
(70%)
Adenocarcinoma 3
(30%)
International Federation of Gynecology and Obstetrics (FIGO) stage
Stage IIB 9
(90%)
Stage IIIB 1
(10%)
Tumor size
Medium length (range) 5.5 cm
(4.3 - 8.4 cm)
Medium depth (range) 3.7 cm
(2.4 - 4.6 cm)
Medium width (range) 4.4 cm
(3.5 - 6.0 cm)
Weekly cycles of chemotherapy
5 weeks 5
(50%)
4 weeks 2
(20%)
3 weeks 1
(10%)
2 weeks 2
(20%)Radiation Oncology 2009, 4:62 http://www.ro-journal.com/content/4/1/62
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(A) The uniformity index of helical tomotherapy for 10 patients with locally advanced cervical cancer Figure 1
(A) The uniformity index of helical tomotherapy for 10 patients with locally advanced cervical cancer. (B) The 
conformal index of helical tomotherapy for with locally advanced cervical cancer.
Table 2: Dose-volume histograms statistics for the organs at risk
Average ± *S.D.
Organ Volume (ml) ± *S.D. Helical tomotherapy Conventional radiotherapy †Decreasing percentage p value
Rectum 43.5 ± 18.2
Mean dose 41.3 ± 5.1 Gy 50.9 ± 1.9 Gy 18.9% < 0.01
V50.4 37.2 ± 30.1% 80.8 ± 12.4% 55.6% < 0.01
V40 68.3 ± 20.9% 95.2 ± 4.2% 35.0% < 0.01
V30 82.2 ± 15.3% 98.4 ± 2.6% 16.6% < 0.01
Bladder 59.8 ± 24.2
Mean dose 40.5 ± 3.5Gy 50.2 ± 2.5Gy 19.3% < 0.01
V50.4 29.5 ± 14.7% 74.4 ± 17.6% 61.3% < 0.01
V45 49.1 ± 13.7% 86.0 ± 11.5% 43.2% < 0.01
V40 57.9 ± 12.6% 91.3 ± 8.5% 36.8% < 0.01
V30 75.7 ± 12.3% 100.0 ± 0% 24.3% < 0.01
Intestine 1523.3 ± 1389.4
Mean dose 25.1 ± 2.4Gy 34.2 ± 4.2Gy 26.3% < 0.01
V50.4 0.4 ± 0.4% 20.0 ± 10.7% 98.2% < 0.01
V40 4.9 ± 3.2% 33.3 ± 13.1% 84.1% < 0.01
V30 23.5 ± 11.9% 59.5 ± 10.4% 61.1% < 0.01
V20 69.2 ± 10.9% 86.6 ± 8.0% 20.1% < 0.01
Right femur 114.4 ± 16.2
V30 15.5 ± 14.2% 23.2 ± 29.1% 19.0% 0.47
Left femur 114.3 ± 14.0
V30 16.1 ± 13.9% 22.3 ± 28.5% 12.9% 0.54
Left pelvic bone 187.3 ± 19.4
V10 99.9 ± 0.1% 93.1 ± 4.8% -6.8% < 0.01
V20 79.1 ± 4.6% 86.2 ± 5.6% 8.2% < 0.01
Right pelvic bone 189.4 ± 20.1
V10 99.9 ± 0.1% 95.5 ± 2.1% -4.4% < 0.01
V20 78.3 ± 4.8% 89.2 ± 3.1% 12.2% < 0.01
*S.D.: standard deviation.
† Decreasing percentage: (conventional radiotherapy - helical tomotherapy)/conventional radiotherapyRadiation Oncology 2009, 4:62 http://www.ro-journal.com/content/4/1/62
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The acute toxicities of GI and GU for locally advanced cer-
vical cancer treated by WPHT are feasible however the
dominant hematologic toxicities are noted in the current
study. The late moderate toxicities for locally advanced
cervical cancer patients treated with CCRT that reported
by previous series are 9.4 - 13% for GI effects and 3 -
14.5% for genitourinary effects [5,21,23]. In the current
study, the subacute grade 3 toxicity is only 1 (10%) for
thrombocytopenia and there are none with GI and GU
effects. (Additional file 1) Compared with WPRT, WPHT
decreases the mean dose to rectum, bladder and intestines
successfully. In addition, the V50 decreasing percentage
for WPHT in rectum, bladder and intestine is 56%, 61%
and 98%, respectively. (Table 2) From the view of physics,
WPHT decreases the mean and high doses to the OARs
entirely when compared with conventional technique and
these physic properties of WPHT reflect the declining rate
of acute and subacute toxicities for gastrointestinal and
genitourinary events successfully. (Additional file 1)
There are numbers of groups that explored how IMRT can
minimize the gastrointestinal, genitourinary and bone
marrow toxicity than conventional RT for gynecologic
cancer patients. When using IMRT techniques for gyneco-
logic treatment, V40 and V30 for the intestine, bladder
and rectum is 25 - 40% and 40 - 57%, 65 - 86% and 88 -
97%, 74 - 84% and 87 - 95%, respectively [24-27]. (Addi-
tional file 2) Compared with previous reports, HT
decreases 80 - 88% of V40 and 40 - 60% of V30 for the
intestine, 11 - 33% of V40 and 14 - 22% of V30 for the
bladder and 8 - 19% of V40 and 6 - 14% of V30 for the rec-
tum than previous IMRT reports, respectively. It also notes
that HT decreases 35% of V45 for the intestine than previ-
ous IMRT reports simultaneously. In other words, HT pro-
vides significantly superiority for decreasing high dose to
these OARs than IMRT does. Therefore, we suggest when
treating the locally advanced cervical cancer patients with
HT, the optimization constraints of V40 and V30 for the
intestine, bladder and rectum could be reconsidered as
5% and 24%, 58% and 76%, 68% and 82%, respectively.
HT can deliver dose to bone marrow exactly in total mar-
row irradiation and reduce the dose to OARs around 51%-
74% when compared with total body irradiation [13]. It
implies that HT can manage bone marrow precisely,
either targeting or sparing. Brixey et al. [8] reported that
acute hematological toxicity was reduced with pelvic
IMRT compared with four-field box techniques in gyneco-
logic cancer patients undergoing chemotherapy. Mell et al.
[28] also provided evidence of an association between the
volume of pelvic BM receiving low-dose radiation (V10,
V20) and pointed out the potential of bone marrow spar-
ing-IMRT could diminish the chronic effects of RT on BM
suppression, improving chemotherapy tolerance. In our
study, the pelvic bones sparing technique did not perform
in the original WPHT plan and the value of V10 for pelvic
bones almost achieving 100% was noted. In our retro-
spective data, 40% of acute moderate hematological tox-
icities happened in the CCRT and 10% of subacute
thrombocytopenia was noted in the following days. It is
noted that the highly conformal doses distribute to target
and large off-target low dose existing simultaneously in
the HT plan. If we target pelvic bone marrow according to
Brixey et al. [8] and set pelvic bone marrow optimal con-
straints directly, HT can provide as much bone marrow
sparing in the low dose as we desired. (Fig. 2) Since June
first, the following cervical cancer patients in our center
were performed pelvic bone sparing technique with
WPHT. Up to day, three locally advanced cervical cancer
patients completed the treatment by WPHT concurrent
with chemotherapy and only grade 1 or 2 acute hemato-
logic toxicities during CCRT are noted. The encouraging
results hints that targeting pelvic bones and setting opti-
mal constraint for pelvic bones can potentially decrease
the acute and subacute clinical toxicities when use WPHT.
There are some limitations in our current study. First, the
small case number and the retrospective study design
make any statistical conclusions very tentative. Second,
the follow-up time is short so the long-term results need
Dose-volume histogram of pelvic bone marrow under the  similar PTV and intestine dose for one patient with original  whole pelvic helical tomotherapy and giving V10 < 90%, V20  <80% replanning whole pelvic helical tomotherapy for com- parisons Figure 2
Dose-volume histogram of pelvic bone marrow 
under the similar PTV and intestine dose for one 
patient with original whole pelvic helical tomother-
apy and giving V10 < 90%, V20 <80% replanning 
whole pelvic helical tomotherapy for comparisons.Radiation Oncology 2009, 4:62 http://www.ro-journal.com/content/4/1/62
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to keep closely follow-up. Third, we do not perform pelvic
bones sparing within this study perhaps this is the reason
for acute hematologic toxicities dominant therefore enroll
more patients by limiting bone marrow radiation dose
with WPHT technique in the future to confirm our obser-
vation is warranted.
Conclusions
To sum up, whole pelvic helical tomotherapy provides
feasible clinical results in patients with locally advanced
cervical carcinoma. Long-term follow-up and to enroll
more locally advanced cervical carcinoma patients by lim-
iting bone marrow radiation dose with WPHT technique
is warranted.
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